Overview

Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Beclomethasone may be effective in treating patients who have graft-versus-host disease of the gastrointestinal tract. PURPOSE: Compassionate use of beclomethasone in treating patients who have graft-versus-host disease of the gastrointestinal tract that has not responded to previous therapy.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Roswell Park Cancer Institute
Treatments:
Beclomethasone
Criteria
DISEASE CHARACTERISTICS:

- Clinically or pathologically confirmed graft-versus-host disease of the
gastrointestinal tract

- Failed standard therapy with or has a contraindication to systemic
immunosuppressive agents

- No clinically significant intestinal infection (confirmed by stool culture)

- No persistent vomiting of all oral intake

- Not a candidate for approved beclomethasone dipropionate Enteron Pharmaceuticals
protocol

PATIENT CHARACTERISTICS:

Age

- 4 to 70

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- Able to swallow medication

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- See Disease Characteristics

Radiotherapy

- Not specified

Surgery

- Not specified